Key result
Ultra-rare variants in 15 genes explain ~2% of atrial fibrillation susceptibility.
Why the study?
The contribution of rare coding genetic variants to the architecture of atrial fibrillation and their utility in gene prioritization remained limited by inadequate sample sizes.
Case-Control (n=1,100,000)
This massive-scale rare variant association study of 130,000 atrial fibrillation cases identified 15 genes associated with AF through rare large-effect variants, showing that ultra-rare protein-disrupting variants explain at least 2% of AF susceptibility.
Answers are grounded in this paper and cite their sources.
Does not yet warrant clinical genetic testing in AF; extends common-variant GWAS by identifying rare large-effect genes across ancestries.
Rare coding genetic variants may exert large effects on risk of common disease, yet their contribution to disease architecture and their utility in gene prioritization remain limited by inadequate sample sizes. Here, we performed a massive-scale rare variant association study (RVAS), analyzing over 1.1 million sequenced participants among which 130,000 had atrial fibrillation (AF). Through a multi-mask burden testing approach, we identified 15 genes significantly associated with AF through rare large-effect variation. Integrative analyses revealed strong convergence between genes implicated by rare and common variation, and highlighted instances where RVAS data may aid in GWAS prioritization. Nevertheless, several RVAS genes were not among GWAS loci (FAM189A2, ACTC1, FNIP1, FBN1), or were not nominated through contemporary GWAS prioritization (KDM5B, ZFP36L2). Finally, we observed that ultra-rare protein-disrupting variants - concentrated in a small number of large-effect size genes - explained at least 2% of AF susceptibility across European and African ancestry groups. These findings refine the genetic architecture of AF, while highlighting the value and cost of RVAS for genomic discovery in common disease.
No takes yet. Share an insight, caveat, or question.
Jurgens et al. (2026) conducted a case-control in Atrial fibrillation (n=1,100,000). Rare coding genetic variants vs. Participants without rare large-effect coding variants was evaluated on Atrial fibrillation susceptibility and gene-level rare variant association. Rare coding variant analysis in >1.1M participants (130,000 AF cases) identified 15 AF-associated genes, with ultra-rare variants explaining ≥2% of AF susceptibility.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: